MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Core Viewpoint - MacroGenics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements about the safety profile of its drug vobramitamab duocarmazine during its clinical trials [1][4]. Company Overview - MacroGenics is a biopharmaceutical company focused on developing monoclonal antibody-based therapeutics for cancer treatment [3]. Allegations and Impact - The class action lawsuit claims that MacroGenics and its CEO made false or misleading statements regarding the safety of vobramitamab duocarmazine, particularly during the TAMARACK Phase 2 study [4]. - On May 9, 2024, interim data revealed that the adverse event rate for vobra duo was over 98.9% and 100% for dosages of 2.0 mg/kg and 2.7 mg/kg, respectively, with over 50% of adverse events being grade 3 or greater. Additionally, there were five fatalities linked to the study, three of which are under investigation [5]. - Following the release of this data, MacroGenics' stock price plummeted by more than 77% [5]. Legal Process - Investors who purchased MacroGenics stock or sold puts during the class period (March 7, 2024, to May 9, 2024) can seek to be appointed as lead plaintiff in the class action lawsuit, with a deadline of September 24, 2024 [1][6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in recent years [7].